Dr. Kevin Li is a Managing Partner at LYZZ Capital, a global biotech venture capital fund. He has more than 20 years of experience as an entrepreneur and active biotech investor in the US and China. Prior to co-founding LYZZ, he was a partner at HBM BioMed China. Kevin was involved in co-founding and managing several successful biotech companies, including ClinChoice, Alpha Biopharma and Mojia Biotech. Dr. Li received his PhD in biology from Indiana University and was a postdoctoral fellow at Stanford University School of Medicine. Dr. Li has served as an investor and board member of many successful biotech companies, including Cathay Industrial Biotech, Chipscreen, Alpha Biopharma, Neurelis, Qpex, Jumpcode, Onchilles and Wugen, among others.